2-methoxy-pyridin-4-yl-derivatives

1. A compound of the Formula (I),

wherein

A represents

wherein the asterisks indicate the bond that is linked to the pyridine group of Formula (I);

R 1 represents cyclopentyl;

R 2 represents methyl, and R 4 represents ethyl or chloro; or

R 2 represents methoxy, and R 4 represents chloro;

R 3 represents —OCH 2 COOH, —OCH 2 CH 2 CH 2 COOH, —OCH 2 CONHCH 2 CH 2 OH, —OCH 2 CH 2 CH 2 CONHCH 2 CH 2 OH, —OCH 2 —(CH 2 ) n —NH—(CH 2 ) m —COOH, —OCH 2 —(CH 2 ) n —N(CH 3 )—(CH 2 ) m —COOH, 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidin-3-carboxylic acid)-1-yl]-ethoxy, 3-[(azetidine-3-carboxylic acid)-1-yl]-propoxy, 3-[(pyrrolidin-3-carboxylic acid)-1-yl]-propoxy, —OCH 2 CH(OH)—CH 2 NH—CH 2 COOH, —OCH 2 CH(OH)—CH 2 NH—CH 2 CH 2 COOH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 COOH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 CH 2 COOH, 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxy-propoxy, 2-hydroxy-3-[(pyrrolidin-3-carboxylic acid)-1-yl]-propoxy, —OCH 2 —(CH 2 ) n —NH—CH 2 CH 2 OH, —OCH 2 —(CH 2 ) n —NH—CH(CH 2 OH) 2 , —OCH 2 —(CH 2 ) n —NH—CH 2 CH(OH)—CH 2 OH, —OCH 2 CH(OH)—CH 2 NH—CH 2 CH 2 OH, —OCH 2 CH(OH)—CH 2 NH—CH(CH 2 OH) 2 , —OCH 2 —(CH 2 ) k —NH—CO—CH 2 OH, —OCH 2 —(CH 2 ) n —NH—CO—CH 2 COOH, —OCH 2 —(CH 2 ) n —NH—CO—CH 2 CH 2 COOH, —OCH 2 CH(OH)—CH 2 NH—CO—(CH 2 )—COOH, —OCH 2 —(CH 2 ) n —N(CH 3 )—CO—CH 2 OH, —OCH 2 —(CH 2 ) n —N(CH 3 )—CO—CH 2 COOH, or —OCH 2 —(CH 2 ) n —N(CH 3 )—CO—CH 2 CH 2 COOH;

n independently represents 1 or 2;

m independently represents 1, 2, or 3; and

k represents 1 or 2;

or a salt thereof.

2. A compound according to claim 1 , wherein the stereocenter of the R 3 groups 2-[(pyrrolidin-3-carboxylic acid)-1-yl]-ethoxy, 3-[(pyrrolidin-3-carboxylic acid)-1-yl]-propoxy, —O—CH 2 CH(OH)—CH 2 NH—CH 2 COOH, —OCH 2 CH(OH)—CH 2 NH—CH 2 CH 2 COOH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 COOH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 CH 2 COOH, 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxy-propoxy, —OCH 2 —(CH 2 ) n —NH—CH 2 CH(OH)—CH 2 OH, —OCH 2 CH(OH)—CH 2 NH—CH 2 CH 2 OH, —OCH 2 CH(OH)—CH 2 NH—CH(CH 2 OH) 2 , and —OCH 2 CH(OH)—CH 2 NH—CO—(CH 2 )—COOH is in the S-configuration, or a salt of such compound.

3. A compound according to claim 1 , wherein the stereocenter of the R 3 groups 2-[(pyrrolidin-3-carboxylic acid)-1-yl]-ethoxy, 3-[(pyrrolidin-3-carboxylic acid)-1-yl]-propoxy, —O—CH 2 CH(OH)—CH 2 NH—CH 2 COOH, —OCH 2 CH(OH)—CH 2 NH—CH 2 CH 2 COOH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 COOH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 CH 2 COOH, 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxy-propoxy, —OCH 2 —(CH 2 ) n —NH—CH 2 CH(OH)—CH 2 OH, —OCH 2 CH(OH)—CH 2 NH—CH 2 CH 2 OH, —OCH 2 CH(OH)—CH 2 NH—CH(CH 2 OH) 2 , and —OCH 2 CH(OH)—CH 2 NH—CO—(CH 2 ) n —COOH is in the R-configuration, or a salt of such compound.

4. A compound according to claim 1 , wherein A represents

wherein the asterisks indicate the bond that is linked to the pyridine group of Formula (I), or a salt of such compound.

5. A compound according to claim 1 , wherein A represents

wherein the asterisk indicates the bond that is linked to the pyridine group of Formula (I), or a salt of such compound.

6. A compound according to claim 1 , wherein A represents

or a salt of such compound.

7. A compound according to claim 1 , wherein R 2 represents methyl, and R 4 represents ethyl or chloro, or a salt of such compound.

8. A compound according to claim 1 , wherein R 2 represents methyl, and R 4 represents ethyl, or a salt of such compound.

9. A compound according to claim 1 , wherein R 2 represents methoxy, and R 4 represents chloro, or a salt of such compound.

10. A compound according to claim 1 , wherein R 3 represents —OCH 2 COOH, —OCH 2 CH 2 CH 2 COOH, —OCH 2 CONHCH 2 CH 2 OH, —OCH 2 CH 2 CH 2 CONHCH 2 CH 2 OH, —OCH 2 —(CH 2 ) n —NH—(CH 2 ) m —COOH, —OCH 2 —(CH 2 ) n —N(CH 3 )—(CH 2 ) m —COOH, 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidin-3-carboxylic acid)-1-yl]-ethoxy, 3-[(azetidine-3-carboxylic acid)-1-yl]-propoxy, —OCH 2 CH(OH)—CH 2 NH—CH 2 COOH, —OCH 2 CH(OH)—CH 2 NH—CH 2 CH 2 COOH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 COOH, 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxy-propoxy, —OCH 2 —(CH 2 ) n —NH—CH 2 CH 2 OH, —OCH 2 —(CH 2 ) n —NH—CH(CH 2 OH) 2 , —OCH 2 —(CH 2 ) n —NH—CH 2 CH(OH)—CH 2 OH, —OCH 2 CH(OH)—CH 2 NH—CH 2 CH 2 OH, —OCH 2 CH(OH)—CH 2 NH—CH(CH 2 OH) 2 , —OCH 2 —(CH 2 ) k —NH—CO—CH 2 OH, —OCH 2 —(CH 2 ) n —NH—CO—CH 2 COOH, —OCH 2 —(CH 2 ) n —NH—CO—CH 2 CH 2 COOH, —OCH 2 CH(OH)—CH 2 NH—CO(CH 2 )—COOH, —OCH 2 —(CH 2 ) n —N(CH 3 )—CO—CH 2 OH, —OCH 2 —(CH 2 ) n —N(CH 3 )—CO—CH 2 COOH, or —OCH 2 —(CH 2 ) n —N(CH 3 )—CO—CH 2 CH 2 COOH, or a salt of such compound.

11. A compound according to claim 1 , wherein R 3 represents —OCH 2 COOH, —OCH 2 CH 2 CH 2 COOH, —OCH 2 CONHCH 2 CH 2 OH, —OCH 2 CH 2 CH 2 CONHCH 2 CH 2 OH, —OCH 2 —(CH 2 ) n —NH—(CH 2 ) m —COOH, —OCH 2 —(CH 2 ) n —N(CH 3 )—(CH 2 ) m —COOH, 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidin-3-carboxylic acid)-1-yl]-ethoxy, 3-[(azetidine-3-carboxylic acid)-1-yl]-propoxy, 3-[(pyrrolidin-3-carboxylic acid)-1-yl]-propoxy, —O—CH 2 CH(OH)—CH 2 NH—CH 2 COOH, —OCH 2 CH(OH)—CH 2 NH—CH 2 CH 2 COOH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 COOH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 CH 2 COOH, 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxy-propoxy, 2-hydroxy-3-[(pyrrolidin-3-carboxylic acid)-1-yl]-propoxy, —OCH 2 —(CH 2 ) n —NH—CH 2 CH 2 OH, —OCH 2 —(CH 2 ) n —NH—CH(CH 2 OH) 2 , —OCH 2 —(CH 2 ) n —NH—CH 2 CH(OH)—CH 2 OH, —OCH 2 CH(OH)—CH 2 NH—CH 2 CH 2 OH, —O—CH 2 CH(OH)—CH 2 NH—CH(CH 2 OH) 2 , —OCH 2 —(CH 2 ) k —NH—CO—CH 2 OH, or —OCH 2 —(CH 2 ) k —N(CH 3 )—CO—CH 2 OH, or a salt of such compound.

12. A compound according to claim 1 , wherein R 3 represents —OCH 2 COOH, —OCH 2 CH 2 CH 2 COOH, —OCH 2 CONHCH 2 CH 2 OH, —OCH 2 CH 2 CH 2 CONHCH 2 CH 2 OH, —OCH 2 —(CH 2 ) n —NH—(CH 2 ) m —COOH, —OCH 2 —(CH 2 ) n —N(CH 3 )—(CH 2 ) m —COOH, 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidin-3-carboxylic acid)-1-yl]-ethoxy, 3-[(azetidine-3-carboxylic acid)-1-yl]-propoxy, 3-[(pyrrolidin-3-carboxylic acid)-1-yl]-propoxy, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 COOH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 CH 2 COOH, 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxy-propoxy, 2-hydroxy-3-[(pyrrolidin-3-carboxylic acid)-1-yl]-propoxy, —OCH 2 —(CH 2 ) n —NH—CH 2 CH 2 OH, —OCH 2 —(CH 2 ) n —NH—CH(CH 2 OH) 2 , —OCH 2 CH(OH)—CH 2 NH—CH 2 CH 2 OH, —O—CH 2 CH(OH)—CH 2 NH—CH(CH 2 OH) 2 , —OCH 2 —(CH 2 ) n —NH—CO—CH 2 COOH, —OCH 2 —(CH 2 ) n —NH—CO—CH 2 CH 2 COOH, —O—CH 2 CH(OH)—CH 2 NH—CO—(CH 2 )—COOH, —OCH 2 —(CH 2 ) n —N(CH 3 )—CO—CH 2 COOH, or —OCH 2 —(CH 2 ) n —N(CH 3 )—CO—CH 2 CH 2 COOH, or a salt of such compound.

13. A compound according to claim 1 , wherein R 3 represents —OCH 2 COOH, —OCH 2 CH 2 CH 2 COOH, —OCH 2 CONHCH 2 CH 2 OH, —OCH 2 CH 2 CH 2 CONHCH 2 CH 2 OH, —OCH 2 —(CH 2 ) n —NH—(CH 2 ) m —COOH, —OCH 2 —(CH 2 ) n —N(CH 3 )—(CH 2 ) m —COOH, 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 3-[(azetidine-3-carboxylic acid)-1-yl]-propoxy, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 COOH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 CH 2 COOH, 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxy-propoxy, —OCH 2 —(CH 2 ) n —NH—CH 2 CH 2 OH, —OCH 2 —(CH 2 ) n —NH—CH(CH 2 OH) 2 , —O—CH 2 CH(OH)—CH 2 NH—CH 2 CH 2 OH, —OCH 2 CH(OH)—CH 2 NH—CH(CH 2 OH) 2 , —OCH 2 —(CH 2 ) k —NH—CO—CH 2 OH, —OCH 2 —(CH 2 ) n —NH—CO—CH 2 COOH, —OCH 2 —(CH 2 ) n —NH—CO—CH 2 CH 2 COOH, —OCH 2 CH(OH)—CH 2 NH—CO—(CH 2 )—COOH, —OCH 2 —(CH 2 ) n —N(CH 3 )—CO—CH 2 COOH, or —OCH 2 —(CH 2 ) n —N(CH 3 )—CO—CH 2 CH 2 COOH, or a salt of such compound.

14. A compound according to claim 1 , wherein R 3 represents —OCH 2 COOH, —OCH 2 CH 2 CH 2 COOH, —OCH 2 —(CH 2 ) n —NH—(CH 2 ) m —COOH, —OCH 2 —(CH 2 ) n —N(CH 3 )—(CH 2 ) m —COOH, 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 3-[(azetidine-3-carboxylic acid)-1-yl]-propoxy, or 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxy-propoxy, or a salt of such compound.

15. A compound according to claim 1 , wherein R 3 represents —OCH 2 CONHCH 2 CH 2 OH, —OCH 2 CH 2 CH 2 CONHCH 2 CH 2 OH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 COOH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 CH 2 COOH, 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxy-propoxy, —OCH 2 —(CH 2 ) n —NH—CH 2 CH 2 OH, —OCH 2 —(CH 2 ) n —NH—CH(CH 2 OH) 2 , —O—CH 2 CH(OH)—CH 2 NH—CH 2 CH 2 OH, or —O—CH 2 CH(OH)—CH 2 NH—CH(CH 2 OH) 2 , or a salt of such compound.

16. A compound according to claim 1 , wherein m represents 1 or 2, or a salt of such compound.

17. A compound according to claim 1 , wherein n represents 1, or a salt of such compound.

18. A compound according to claim 1 , wherein

A represents

wherein the asterisk indicates the bond that is linked to the pyridine group of Formula (I);

R 1 represents cyclopentyl;

R 2 represents methyl, and R 4 represents ethyl or chloro; or

R 2 represents methoxy, and R 4 represents chloro; and

R 3 represents —OCH 2 COOH, —OCH 2 CH 2 CH 2 COOH, —OCH 2 CONHCH 2 CH 2 OH, —OCH 2 CH 2 CH 2 CONHCH 2 CH 2 OH, —OCH 2 —(CH 2 ) 1-2 —NH—(CH 2 ) 1-2 —COOH, —OCH 2 —CH 2 —NH—(CH 2 ) 3 —COOH, —OCH 2 —(CH 2 ) 1-2 —N(CH 3 )—(CH 2 ) 1-2 —COOH, 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidin-3-carboxylic acid)-1-yl]-ethoxy, 3-[(azetidine-3-carboxylic acid)-1-yl]-propoxy, —OCH 2 CH(OH)—CH 2 NH—CH 2 COOH, —OCH 2 CH(OH)—CH 2 NH—CH 2 CH 2 COOH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 COOH, 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxy-propoxy, —OCH 2 —(CH 2 ) 1-2 —NH—CH 2 CH 2 OH, —OCH 2 —(CH 2 ) 1-2 —NH—CH(CH 2 OH) 2 , —OCH 2 —(CH 2 ) 1-2 —NH—CH 2 CH(OH)—CH 2 OH, —OCH 2 CH(OH)—CH 2 NH—CH 2 CH 2 OH, —OCH 2 CH(OH)—CH 2 NH—CH(CH 2 OH) 2 , —OCH 2 —(CH 2 ) 2 —NH—CO—CH 2 OH, —OCH 2 —(CH 2 ) 2 —NH—CO—CH 2 COOH, —OCH 2 —(CH 2 ) 2 —NH—CO—CH 2 CH 2 COOH, —OCH 2 CH(OH)—CH 2 NH—CO—(CH 2 ) 1-2 COOH, —OCH 2 —(CH 2 ) 2 —N(CH 3 )—CO—CH 2 OH, —OCH 2 —(CH 2 ) 2 —N(CH 3 )—CO—CH 2 COOH, or —OCH 2 —(CH 2 ) 2 —N(CH 3 )—CO—CH 2 CH 2 COOH, or a salt of such compound.

19. A compound according to claim 1 , wherein R 3 represents —OCH 2 COOH, —OCH 2 CH 2 CH 2 COOH, —OCH 2 CONHCH 2 CH 2 OH, —OCH 2 CH 2 CH 2 CONHCH 2 CH 2 OH, —OCH 2 —(CH 2 ) 1-2 —NH—(CH 2 ) 1-2 —COOH, —OCH 2 —CH 2 —NH—(CH 2 ) 3 —COOH, —OCH 2 —(CH 2 ) 1-2 —N(CH 3 )—(CH 2 ) 1-2 —COOH, 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidin-3-carboxylic acid)-1-yl]-ethoxy, 3-[(azetidine-3-carboxylic acid)-1-yl]-propoxy, —OCH 2 CH(OH)—CH 2 NH—CH 2 COOH, —OCH 2 CH(OH)—CH 2 NH—CH 2 CH 2 COOH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 COOH, —OCH 2 CH(OH)—CH 2 N(CH 3 )—CH 2 CH 2 COOH, 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxy-propoxy, —OCH 2 —(CH 2 ) 1-2 —NH—CH 2 CH 2 OH, —OCH 2 —(CH 2 ) 1-2 —NH—CH(CH 2 OH) 2 , —OCH 2 —(CH 2 ) 1-2 —NH—CH 2 CH(OH)—CH 2 OH, —OCH 2 CH(OH)—CH 2 NH—CH 2 CH 2 OH, —OCH 2 CH(OH)—CH 2 NH—CH(CH 2 OH) 2 , —OCH 2 —(CH 2 ) 2 —NH—CO—CH 2 OH, —OCH 2 —(CH 2 ) 1-2 —NH—CO—CH 2 COOH, —OCH 2 —(CH 2 ) 1-2 —NH—CO—CH 2 CH 2 COOH, —OCH 2 CH(OH)—CH 2 NH—CO—(CH 2 ) 1-2 COOH, —OCH 2 —(CH 2 ) 2 —N(CH 3 )—CO—CH 2 OH, —OCH 2 —(CH 2 ) 2 —N(CH 3 )—CO—CH 2 COOH, or —OCH 2 —(CH 2 ) 2 —N(CH 3 )—CO—CH 2 CH 2 COOH, or a salt of such compound.

20. A compound according to claim 1 selected from the group consisting of:

3-(2-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-ethylamino)-propionic acid,

1-(2-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxyl}-ethyl)-azetidine-3-carboxylic acid,

(S)-1-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-3-(2-hydroxy-ethylamino)-propan-2-ol,

2-((S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-propane-1,3-diol,

{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-acetic acid,

4-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-butyric acid,

(2-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-ethylamino)-acetic acid,

1-(2-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-ethyl)-pyrrolidine-3-carboxylic acid,

((S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-acetic acid,

3-((S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-propionic acid,

[((S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-methyl-amino]-acetic acid,

1-((S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-azetidine-3-carboxylic acid,

2-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-N-(2-hydroxy-ethyl)-acetamide,

N—((S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-malonamic acid,

N—((S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-succinamic acid,

[(2-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-ethyl)-methyl-amino]-acetic acid,

3-[(2-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-ethyl)-methyl-amino]-propionic acid,

(3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propylamino)-acetic acid,

3-(3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propylamino)-propionic acid,

[(3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propyl)-methyl-amino]-acetic acid,

3-[(3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propyl)-methyl-amino]-propionic acid,

1-(3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propyl)-azetidine-3-carboxylic acid,

2-(2-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-ethylamino)-ethanol,

2-(3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propylamino)-ethanol,

2-(2-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-ethylamino)-propane-1,3-diol,

2-(3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propylamino)-propane-1,3-diol,

3-(2-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-ethylamino)-propane-1,2-diol,

3-(3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propylamino)-propane-1,2-diol,

N-(3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propyl)-2-hydroxy-acetamide,

N-(3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propyl)-2-hydroxy-N-methyl-acetamide,

N-(3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propyl)-malonamic acid,

N-(3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propyl)-succinamic acid,

N-(3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propyl)-N-methyl-malonamic acid,

N-(3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propyl)-N-methyl-succinamic acid,

4-{2-chloro-4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methoxy-phenoxy}-butyric acid,

4-{2-chloro-4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methoxy-phenoxy}-N-(2-hydroxy-ethyl)-butyramide,

3-(2-{2-chloro-4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methoxy-phenoxy}-ethylamino)-propionic acid,

N-(3-{2-chloro-4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methoxy-phenoxy}-propyl)-2-hydroxy-acetamide,

4-((2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)ethyl)amino)butanoic acid, and

4-(2-chloro-4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)butanoic acid,

or a salt of such compounds.

21. A compound according to claim 1 selected from the group consisting of:

2-(2-chloro-4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)acetic acid,

2-(2-chloro-4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methyl-phenoxy)-N-(2-hydroxyethyl)acetamide,

3-((2-(2-chloro-4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)ethyl)amino)propanoic acid,

1-(2-(2-chloro-4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)ethyl)azetidine-3-carboxylic acid,

2-((2-(2-chloro-4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)ethyl)amino)ethanol,

4-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-N-(2-hydroxyethyl)butanamide,

(S)-3-((3-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)(methyl)amino)propanoic acid,

(R)-3-((3-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)(methyl)amino)propanoic acid,

3-((2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)ethyl)amino)-3-oxopropanoic acid,

4-((2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)ethyl)amino)-4-oxobutanoic acid,

2-((2-(2-chloro-4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methoxyphenoxy)ethyl)amino)acetic acid,

1-(2-(2-chloro-4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methoxyphenoxy)ethyl)azetidine-3-carboxylic acid,

2-(4-(3-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl)-2-ethyl-6-methylphenoxy)acetic acid,

4-(4-(3-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl)-2-ethyl-6-methylphenoxy)butanoic acid,

2-((2-(4-(3-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl)-2-ethyl-6-methylphenoxy)ethyl)amino)acetic acid,

2-((2-(4-(3-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl)-2-ethyl-6-methylphenoxy)ethyl)(methyl)amino)acetic acid,

3-((2-(4-(3-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl)-2-ethyl-6-methylphenoxy)ethyl)amino)propanoic acid,

1-(2-(4-(3-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl)-2-ethyl-6-methylphenoxy)ethyl)azetidine-3-carboxylic acid,

2-((3-(4-(3-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl)-2-ethyl-6-methylphenoxy)propyl)amino)acetic acid,

2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,3,4-oxadiazol-2-yl)-2-ethyl-6-methylphenoxy)acetic acid,

4-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,3,4-oxadiazol-2-yl)-2-ethyl-6-methylphenoxy)butanoic acid,

3-((2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,3,4-oxadiazol-2-yl)-2-ethyl-6-methylphenoxy)ethyl)amino)propanoic acid,

1-(2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,3,4-oxadiazol-2-yl)-2-ethyl-6-methylphenoxy)ethyl)azetidine-3-carboxylic acid,

(S)-1-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,3,4-oxadiazol-2-yl)-2-ethyl-6-methylphenoxy)-3-(2-hydroxyethyl)amino)propan-2-ol,

(S)-2-((3-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,3,4-oxadiazol-2-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)amino)propane-1,3-diol, and

(S)-4-((3-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,3,4-oxadiazol-2-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)amino)-4-oxobutanoic acid,

or a salt of such compounds.

22. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

23. A method of reducing the number of circulating and infiltrating T- and B-lymphocytes in a patient in need thereof, comprising administering to the patient a pharmaceutically active amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.